RANI Rani Therapeutics Holdings, Inc.

NASDAQ
$0.65

Rani Therapeutics Holdings, Inc. (RANI) is expected to report earnings on February 8, 2027, after the market close. The consensus earnings estimate is a loss of $0.06 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +15.7% since its last earnings release on November 9, 2026.

Rani Therapeutics Beat Consensus Estimates
Monday, November 9, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 8
Monday · 4:05 PM ET
Earnings Whisper
-
vs ($0.06)
Rev est $1.7M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.57

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Rani Therapeutics Holdings, Inc.

Rani Therapeutics is a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics.

Sector

Healthcare

Industry

Drug Delivery

Charts powered in part by Lightweight Charts™ by TradingView.